Scarica l'app Stockscreener
0.00
100.00%
-2.36
Eagle Pharmaceuticals Inc Borsa (EGRX) Ultime notizie
ACA Pharma secures fast-track approval for Eagle Pharmaceuticals' RYANODEX® in Macau - PRWeb
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Eagle-Tribune
UPDATENika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June ... - Eagle-Tribune
Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Eagle-Tribune
Nika Pharmaceuticals, Inc. to Present at the Life Sciences Virtual Investor Forum June 11th-12th - Eagle-Tribune
U.S. Vasopressin Market Projected to Witness Massive Growth in Critical Care | Pfizer, Ferring Pharmaceuticals - openPR.com
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm! - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
EGRX STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
EGRX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Most Pittsburgh area Rite Aid locations to transfer prescriptions to Giant Eagle Pharmacy - Yahoo Finance
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Eagle-Tribune
Heparin-Induced Thrombocytopenia (HIT) Market: A Serious Drug Reaction Explained 2025-2033 - openPR.com
Bacterial Pneumonia Market: How to Identify and Treat This Serious Lung Infection - openPR.com
ATNM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. ... - Eagle-Tribune
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Eagle-Tribune
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - Eagle-Tribune
Shareholders that lost money on Eagle Pharmaceuticals, Inc. (EGRX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a ... - Eagle-Tribune
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Bacterial Pneumonia Therapeutics Market 2032: Clinical - openPR.com
INVESTOR ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors ... - Eagle-Tribune
Press Release Distribution & PR Platform - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - The AM Reporter
EmpiRx Health Partners with Giant Eagle to Transform Pharmacy Benefits Care - PR Newswire
Eagle Pharmaceuticals Shares Turn Positive After Positive 2022 Outlook - marketscreener.com
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender AgreementHagens Berman - ACCESS Newswire
Latham Watkins Advises Eagle Pharmaceuticals in Royalty Monetization With Blue Owl Capital - Latham & Watkins LLP
Eagle Pharmaceuticals Announces $69 Mln Agreement To Monetize Bendeka Royalties - marketscreener.com
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties - The Manila Times
Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below 200-Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharmaceuticals announces amendment to limited duration stockholder rights plan - Marketscreener.com
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by IFP Advisors Inc - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Eagle Pharmaceuticals, Inc. (EGRX) - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
0.93%
Capitalizzazione:
|
Volume (24 ore):